The FDA has approved the sBLA for once every 4 weeks lecanemab-irmb (Leqembi®) intravenous maintenance dosing.

The updated label allows physicians to prescribe Izervay without a limitation on duration for patients with geographic ...

Inserting, monitoring, and maintaining peripheral venous access is an integral component of neonatal nursing care. Although complications associated with peripheral vascular devices are typically ...

We've verified that the organization Authenticator-Extension controls the domain: ...